BMRN
BioMarin Pharmaceutical Inc.
Biotechnology
Market Cap$10.41B
5Y Perf.-49.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
BMRN vs FOLD
Revenue, margins, valuation, and 5-year total return — side by side.
FOLD
Amicus Therapeutics, Inc.
Biotechnology
Market Cap$4.55B
5Y Perf.+15.9%
BMRN vs FOLD — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | BMRN | FOLD |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $10.41B | $4.55B |
| Revenue (TTM) | $3.24B | $634M |
| Net Income (TTM) | $269M | $-27M |
| Gross Margin | 75.9% | 87.9% |
| Operating Margin | 13.8% | 5.2% |
| Forward P/E | 12.6x | 40.6x |
| Total Debt | $643M | $483M |
| Cash & Equiv. | $1.31B | $214M |
BMRN vs FOLD — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
BMRN
FOLD
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| BioMarin Pharmaceut… (BMRN) | 100 | 50.8 | -49.2% |
| Amicus Therapeutics… (FOLD) | 100 | 115.9 | +15.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: BMRN vs FOLD
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: BMRN and FOLD are tied at the top with 3 categories each — the right choice depends on your priorities. Amicus Therapeutics, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
BMRN
BioMarin Pharmaceutical Inc.
The Defensive Pick
BMRN has the current edge in this matchup, primarily because of its strength in sleep-well-at-night.
- Lower volatility, beta 0.65, Low D/E 10.6%, current ratio 5.21x
- Lower P/E (12.6x vs 40.6x)
- 8.3% margin vs FOLD's -4.3%
Best for: sleep-well-at-night
FOLD
Amicus Therapeutics, Inc.
The Income Pick
FOLD is the clearest fit if your priority is income & stability and growth exposure.
- beta 0.63
- Rev growth 20.0%, EPS growth 51.2%, 3Y rev CAGR 24.4%
- 119.2% 10Y total return vs BMRN's -35.6%
Best for: income & stability and growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | FOLD | 20.0% revenue growth vs BMRN's 12.9% |
| Value | BMRN | Lower P/E (12.6x vs 40.6x) |
| Quality / Margins | BMRN | 8.3% margin vs FOLD's -4.3% |
| Stability / Safety | FOLD | Beta 0.63 vs BMRN's 0.65 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | FOLD | +137.9% vs BMRN's -8.8% |
| Efficiency (ROA) | BMRN | 3.4% ROA vs FOLD's -3.2%, ROIC 7.4% vs 5.3% |
BMRN vs FOLD — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
BMRN vs FOLD — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLBMRNLAGGINGFOLD
FOLDAmicus Therapeutics, …
2leads
BMRNBioMarin Pharmaceutic…
3leads
6 Total Categories
CATEGORYLEADERvs FOLDMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BMRN4/6
Valuation MetricsMultiples, price ratios, and targets
BMRN5/6
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BMRN8/9
Total Returns1Y, 3Y, 5Y total returns with dividends
FOLD6/6
Risk & VolatilityBeta, volatility, and downside exposure
FOLD2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
BMRN leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BMRN is the larger business by revenue, generating $3.2B annually — 5.1x FOLD's $634M. BMRN is the more profitable business, keeping 8.3% of every revenue dollar as net income compared to FOLD's -4.3%. On growth, FOLD holds the edge at +23.7% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | BMRNBioMarin Pharmace… | FOLDAmicus Therapeuti… |
|---|---|---|
| RevenueTrailing 12 months | $3.2B | $634M |
| EBITDAEarnings before interest/tax | $521M | $40M |
| Net IncomeAfter-tax profit | $269M | -$27M |
| Free Cash FlowCash after capex | $767M | $30M |
| Gross MarginGross profit ÷ Revenue | +75.9% | +87.9% |
| Operating MarginEBIT ÷ Revenue | +13.8% | +5.2% |
| Net MarginNet income ÷ Revenue | +8.3% | -4.3% |
| FCF MarginFCF ÷ Revenue | +23.7% | +4.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +2.8% | +23.7% |
| EPS Growth (YoY)Latest quarter vs prior year | -43.2% | -89.0% |
BMRN leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
BMRN leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
On an enterprise value basis, BMRN's 15.9x EV/EBITDA is more attractive than FOLD's 114.9x.
| Metric | BMRNBioMarin Pharmace… | FOLDAmicus Therapeuti… |
|---|---|---|
| Market CapShares × price | $10.4B | $4.5B |
| Enterprise ValueMkt cap + debt − cash | $9.7B | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | 30.07x | -164.85x |
| Forward P/EPrice ÷ next-FY EPS est. | 12.60x | 40.62x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 15.89x | 114.88x |
| Price / SalesMarket cap ÷ Revenue | 3.23x | 7.17x |
| Price / BookPrice ÷ Book value/share | 1.75x | 16.29x |
| Price / FCFMarket cap ÷ FCF | 14.36x | 152.43x |
BMRN leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
BMRN leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
BMRN delivers a 4.4% return on equity — every $100 of shareholder capital generates $4 in annual profit, vs $-12 for FOLD. BMRN carries lower financial leverage with a 0.11x debt-to-equity ratio, signaling a more conservative balance sheet compared to FOLD's 1.76x. On the Piotroski fundamental quality scale (0–9), BMRN scores 5/9 vs FOLD's 4/9, reflecting solid financial health.
| Metric | BMRNBioMarin Pharmace… | FOLDAmicus Therapeuti… |
|---|---|---|
| ROE (TTM)Return on equity | +4.4% | -12.0% |
| ROA (TTM)Return on assets | +3.4% | -3.2% |
| ROICReturn on invested capital | +7.4% | +5.3% |
| ROCEReturn on capital employed | +8.1% | +5.1% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 |
| Debt / EquityFinancial leverage | 0.11x | 1.76x |
| Net DebtTotal debt minus cash | -$669M | $269M |
| Cash & Equiv.Liquid assets | $1.3B | $214M |
| Total DebtShort + long-term debt | $643M | $483M |
| Interest CoverageEBIT ÷ Interest expense | 16.96x | 1.00x |
BMRN leads this category, winning 8 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
FOLD leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in FOLD five years ago would be worth $14,862 today (with dividends reinvested), compared to $6,959 for BMRN. Over the past 12 months, FOLD leads with a +137.9% total return vs BMRN's -8.8%. The 3-year compound annual growth rate (CAGR) favors FOLD at 6.0% vs BMRN's -17.4% — a key indicator of consistent wealth creation.
| Metric | BMRNBioMarin Pharmace… | FOLDAmicus Therapeuti… |
|---|---|---|
| YTD ReturnYear-to-date | -9.0% | +1.5% |
| 1-Year ReturnPast 12 months | -8.8% | +137.9% |
| 3-Year ReturnCumulative with dividends | -43.6% | +19.0% |
| 5-Year ReturnCumulative with dividends | -30.4% | +48.6% |
| 10-Year ReturnCumulative with dividends | -35.6% | +119.2% |
| CAGR (3Y)Annualised 3-year return | -17.4% | +6.0% |
FOLD leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
FOLD leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
FOLD is the less volatile stock with a 0.63 beta — it tends to amplify market swings less than BMRN's 0.65 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FOLD currently trades 99.9% from its 52-week high vs BMRN's 81.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | BMRNBioMarin Pharmace… | FOLDAmicus Therapeuti… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.65x | 0.63x |
| 52-Week HighHighest price in past year | $66.28 | $14.50 |
| 52-Week LowLowest price in past year | $50.76 | $5.51 |
| % of 52W HighCurrent price vs 52-week peak | +81.7% | +99.9% |
| RSI (14)Momentum oscillator 0–100 | 48.7 | 72.2 |
| Avg Volume (50D)Average daily shares traded | 1.8M | 3.0M |
FOLD leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates BMRN as "Buy" and FOLD as "Buy". Consensus price targets imply 65.6% upside for BMRN (target: $90) vs 0.1% for FOLD (target: $15).
| Metric | BMRNBioMarin Pharmace… | FOLDAmicus Therapeuti… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $89.64 | $14.50 |
| # AnalystsCovering analysts | 41 | 24 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
BMRN leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). FOLD leads in 2 (Total Returns, Risk & Volatility).
Best OverallBioMarin Pharmaceutical Inc. (BMRN)Leads 3 of 6 categories
Loading custom metrics...
BMRN vs FOLD: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is BMRN or FOLD a better buy right now?
For growth investors, Amicus Therapeutics, Inc.
(FOLD) is the stronger pick with 20. 0% revenue growth year-over-year, versus 12. 9% for BioMarin Pharmaceutical Inc. (BMRN). BioMarin Pharmaceutical Inc. (BMRN) offers the better valuation at 30. 1x trailing P/E (12. 6x forward), making it the more compelling value choice. Analysts rate BioMarin Pharmaceutical Inc. (BMRN) a "Buy" — based on 41 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — BMRN or FOLD?
On forward P/E, BioMarin Pharmaceutical Inc.
is actually cheaper at 12. 6x.
03Which is the better long-term investment — BMRN or FOLD?
Over the past 5 years, Amicus Therapeutics, Inc.
(FOLD) delivered a total return of +48. 6%, compared to -30. 4% for BioMarin Pharmaceutical Inc. (BMRN). Over 10 years, the gap is even starker: FOLD returned +119. 2% versus BMRN's -35. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — BMRN or FOLD?
By beta (market sensitivity over 5 years), Amicus Therapeutics, Inc.
(FOLD) is the lower-risk stock at 0. 63β versus BioMarin Pharmaceutical Inc. 's 0. 65β — meaning BMRN is approximately 3% more volatile than FOLD relative to the S&P 500. On balance sheet safety, BioMarin Pharmaceutical Inc. (BMRN) carries a lower debt/equity ratio of 11% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — BMRN or FOLD?
By revenue growth (latest reported year), Amicus Therapeutics, Inc.
(FOLD) is pulling ahead at 20. 0% versus 12. 9% for BioMarin Pharmaceutical Inc. (BMRN). On earnings-per-share growth, the picture is similar: Amicus Therapeutics, Inc. grew EPS 51. 2% year-over-year, compared to -18. 6% for BioMarin Pharmaceutical Inc.. Over a 3-year CAGR, FOLD leads at 24. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — BMRN or FOLD?
BioMarin Pharmaceutical Inc.
(BMRN) is the more profitable company, earning 10. 8% net margin versus -4. 3% for Amicus Therapeutics, Inc. — meaning it keeps 10. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMRN leads at 16. 6% versus 5. 4% for FOLD. At the gross margin level — before operating expenses — FOLD leads at 87. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is BMRN or FOLD more undervalued right now?
On forward earnings alone, BioMarin Pharmaceutical Inc.
(BMRN) trades at 12. 6x forward P/E versus 40. 6x for Amicus Therapeutics, Inc. — 28. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BMRN: 65. 6% to $89. 64.
08Which pays a better dividend — BMRN or FOLD?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is BMRN or FOLD better for a retirement portfolio?
For long-horizon retirement investors, Amicus Therapeutics, Inc.
(FOLD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 63), +119. 2% 10Y return). Both have compounded well over 10 years (FOLD: +119. 2%, BMRN: -35. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between BMRN and FOLD?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: BMRN is a mid-cap quality compounder stock; FOLD is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(BMRN: 2.8% · FOLD: 23.7%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.